Compare CSTL & MOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CSTL | MOV |
|---|---|---|
| Founded | 2007 | 1961 |
| Country | United States | United States |
| Employees | N/A | 1386 |
| Industry | Medical Specialities | Consumer Specialties |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 611.1M | 568.3M |
| IPO Year | 2019 | N/A |
| Metric | CSTL | MOV |
|---|---|---|
| Price | $21.16 | $38.33 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 1 |
| Target Price | ★ $45.50 | $31.50 |
| AVG Volume (30 Days) | ★ 468.8K | 161.4K |
| Earning Date | 05-06-2026 | 05-28-2026 |
| Dividend Yield | N/A | ★ 5.17% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $344,229,000.00 | N/A |
| Revenue This Year | $2.42 | $1.92 |
| Revenue Next Year | $12.69 | $0.67 |
| P/E Ratio | ★ N/A | $25.52 |
| Revenue Growth | ★ 3.66 | N/A |
| 52 Week Low | $14.59 | $14.78 |
| 52 Week High | $44.28 | $35.78 |
| Indicator | CSTL | MOV |
|---|---|---|
| Relative Strength Index (RSI) | 47.27 | 84.66 |
| Support Level | $17.72 | $23.23 |
| Resistance Level | $24.46 | N/A |
| Average True Range (ATR) | 1.12 | 1.44 |
| MACD | 0.37 | 1.09 |
| Stochastic Oscillator | 74.65 | 96.14 |
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.
Movado Group Inc designs, develops, sources, markets, and distributes fine watches in the United States and internationally. It operates through the Watch and Accessory Brands and Company Stores segment. The Watch and Accessory Brands segment includes the designing, manufacturing, and distribution of watches and, to a lesser extent, jewelry and other accessories of quality owned brands and licensed brands. Its Company Stores segment includes the company's retail outlet locations in the United States and Canada. It generates maximum revenue from the Watch and Accessory Brands segment. Geographically, it derives the majority of its revenue from its international locations.